ProCE Banner Activity

CE / CME

Pivotal Updates to the Guidelines for Managing Heart Failure With Reduced Ejection Fraction

PCE On Demand Live Presentation

New medical therapies have been approved in patients with heart failure with reduced ejection fraction (HFrEF) in the last several years; however, adoption into clinical practice has been suboptimal. Increasing the awareness of new therapies and the importance of achieving target doses while improving patient adherence and access to these new medications are vital to improving HFrEF outcomes in the outpatient setting. In this 1-hour webcast, 2 cardiology experts review the evidence and latest guidance for treating patients with HFrEF. Cases will be presented to demonstrate how to formulate optimal medication regimens for managing special populations.

In Collaboration With the Academy of Physician Associates in Cardiology

APAC Logo

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: May 16, 2022

Expiration: May 15, 2023

No longer available for credit.

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Lauren S. Eyadiel

Lauren S. Eyadiel, MS, MMS, PA-C, SLP, FHFSA

Assistant Professor
Heart Failure-Certified
Department of PA Studies
Wake Forest University School of Medicine
Advanced Heart Failur, Heart Transplant, and Mechanical Circulatory Support
Atrium Health Wake Forest Baptist
Winston Salem, North Carolina

Lee R. Goldberg

Lee R. Goldberg, MD, MPH, FACC

Professor of Medicine
Division of Cardiovascular Medicine
Department of Medicine
Section Chief
Advanced Heart Failure and Cardiac Transplant
University of Pennsylvania
Philadelphia, Pennsylvania

Acknowledgement

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Target Audience

NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the most recent evidence included in guideline updates for the treatment of HFrEF

  • Design an optimal medication regimen for a patient with HFrEF with consideration for target doses and minimizing adverse events

  • Identify strategies to improve patient access and adherence to GDMT in order to maximize outcomes

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Butler: consultant/advisor/speaker: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche, Vifor.

Ms Eyadiel: has no relevant financial relationships to disclose.

Dr Goldberg: consultant/advisor/speaker: Abbott, Respicardia/Zoll, Viscardia; researcher: Respicardia/Zoll.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: May 16, 2022
Expiration date: May 15, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP Course Advisor: Darcy Thiesen, CNP, MSN, Park Nicollet Heart and Vascular Center, St. Louis Park, Minnesota

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until May 15, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.